Comparative permeability studies with radioactive and nonradioactive risedronate sodium from self-microemulsifying drug delivery system and solution

Drug Development and Industrial Pharmacy

Volumn 41, Issue 9, 2015, Pages 1493-1498

  Ilem Ozdemir, Derya ^a   Gundogdu, Evren ^a   Ekinci, Meliha ^a   Ozgenc, Emre ^a   Asikoglu, Makbule ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Cell culture; Microemulsion; Permeability; Risedronate sodium; Technetium 99m

Indexed keywords

COSURFACTANT; CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; RISEDRONIC ACID; SORBITAN OLEATE; SOYBEAN OIL; TECHNETIUM 99M; BONE DENSITY CONSERVATION AGENT; EMULSION; EXCIPIENT; RADIOPHARMACEUTICAL AGENT; SOLUTION AND SOLUBILITY; SURFACTANT; TECHNETIUM;

ARTICLE; CACO 2 CELL LINE; COLON ADENOCARCINOMA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MICROEMULSION; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; CHEMISTRY; COMPARATIVE STUDY; EMULSION; MEDICINAL CHEMISTRY; PERMEABILITY; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY;

BONE DENSITY CONSERVATION AGENTS; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; EXCIPIENTS; HUMANS; PERMEABILITY; PHARMACEUTICAL SOLUTIONS; RADIOPHARMACEUTICALS; RISEDRONATE SODIUM; SOLUBILITY; SOYBEAN OIL; SURFACE-ACTIVE AGENTS; TECHNETIUM;

EID: 84964284558     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.959022     Document Type: Article

References (36)

1. Bartl R, Frisch B, Von Tresckow E, Bartl C. Biphosphonates in medical practice. Heidelberg, German: Spriger-Verlag; 2007: 35-70.
2. Rolf WS, Jan den H. Chromatographic analysis of bisphosphonates. Pharm World Sci 1999; 21: 1-21.
3. Chaiamnuay S, Saag KG. Postmenopausal osteoporosis. Rev Endocr Metab Dis 2006; 7: 101-2.
4. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36: 315-28.
5. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58: 228-98.
6. Kos M, Luczak K. Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonization. Biosci Hypotheses 2009; 2: 34.
7. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-99.
8. Marvola T, Marvola J, Kanerva H, et al. Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules for local treatment in colon. Int J Pharm 2008; 349: 24-9.
9. Dilworth JR, Parrott SJ. The biomedical chemistry of technetium. Chem Soc Rev 1998; 27: 43-55.
10. Jurisson SS, Lydon JD. Potential technetium small molecule radiopharmaceuticals. Chem Rev 1999; 99: 2205-18.
11. Pauwels EK, Stokkel MP. Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice. Q J Nucl Med 2001; 45: 18-26.
12. Mendez-Rojas MA, Kharisov BI, Tsivadze AY. Recent advances on technetium complexes: Coordination chemistry and medical applications. J Coord Chem 2006; 59: 1-63.
13. Bartholom MD, Louie AS, Valliant JF, Zubieta J. Technetium and gallium derived radiopharmaceuticals: Comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem Rev 2010; 110: 2903-20.
14. El-Mabhout AA, Mercer JR. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases. Appl Radiat Isot 2005; 62: 541-9.
15. Mari C, Catafau A, Carrio I. Bone scintigraphy and metabolic disorders. Q J Nucl Med 1999; 43: 259-67.
16. Palma E, Oliveira BL, Correia JD, et al. A new bisphosphonatecontaining 99mTc(I) tricarbonyl complex potentially useful as boneseeking agent: Synthesis and biological evaluation. J Biol Inorg Chem 2007; 12: 667-79.
17. Shigematsu M, Shiomi S, Iwao H, Ochi H. New bone-seeking agent: Animal study of Tc-99m-incadronate. Ann Nucl Med 2002; 16: 55-9.
18. Schampt K, Schreder SA, Dressman J. Development of an/in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance. Eur J Pharm Biopharm 2006; 62: 227-34.
19. Kovarik JM, Mueller EA, Van Bree JB, et al. Reduced interand intra individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444-7.
20. Chae GS, Lee JS, Kim SH, et al. Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEEDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. Int J Pharm 2005; 301: 6-14.
21. Sousa JJ, Sousa A, Moura MJ, et al. The influence of core materials and film coating on the drug release from coated pellets. Int J Pharm 2002; 233: 11-122.
22. Constantinides PP, Yiv SH. Particle size determination of phaseinverted water-in-oil microemulsions under different dilution and storage conditions. Int J Pharm 1995; 115: 225-34.
23. Shah NH, Carvajal MT, Patel CI, et al. Self-emulsifying drug delivery systems (SEEDS) with polyglycolysed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994; 106: 15-23.
24. Charman SA, Charman WN, Rogge MC, et al. Self-emulsifying drug delivery systems: Formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm Res 1992; 9: 87-93.
25. Parmar N, Singla N, Amin S, Kohli K. Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded self nanoemulsifying drug delivery system. Colloids Surf B 2011; 86: 327-38.
26. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self microemulsifying drug delivery systems. Eur J Biopharm 2006; 63: 288-94.
27. Ç elik N. Radiolabeling of risedronate sodium with 99mTc for bone imaging [master thesis]. Izmir: Ege University Radiopharmacy Department; 2012.
28. Ghassabian S, Wright AL, Dejager AD, Smith MT. Development and validation of sensitive solid phase extraction (SPE) method using high performance liquid chromatography/tandem mass spectrometry for determination of risedronate concentrations in human plasma. J Chromatogr B 2012; 881-882: 34-41.
29. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46: 27-43.
30. Kogan A, Kesselman E, Danino D, et al. Viability and permeability across Caco-2 cells of carbamazepine solubilized in fully dilutable microemulsions. Colloids Surf B 2008; 66: 1-12.
31. Yee S. In vivo permeability across Caco-2 cells can predict in vivo (small intestine) in man-fact or myth. Pharm Res 1997; 14: 763-6.
32. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm 2006; 63: 288-94.
33. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 2004; 21: 261-70.
34. Swenson ES, Curatolo WJ. Means to enhance penetration. Adv Drug Deliv Rev 1992; 8: 39-42.
35. Konsoula R, Barile FA. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol In Vitro 2005; 19: 675-84.
36. Maestrelli F, Zerrouk N, Chemtob C, Mura P. Influence of chitosan and its glutamate and hydrochloride salts on naproxen dissolution rate and permeation across Caco-2 cells. Int J Pharm 2004; 271: 257-67.